Literature DB >> 8413656

Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.

J R Schultz1, J G Verstuyft, E L Gong, A V Nichols, E M Rubin.   

Abstract

High-density lipoprotein (HDL) contains two major proteins, apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), comprising about 70% and 20% of the total HDL protein mass, respectively. HDL exists in human plasma in two main forms, one containing apoA-I with apoA-II (AI/AII-HDL) and another containing apoA-I without apoA-II (AI-HDL). A strong inverse relationship exists between total plasma HDL concentration and atherosclerosis, but the results of studies examining the relationship between AI-HDL and AI/AII-HDL and atherosclerosis have been conflicting. To determine whether these two HDL populations have different effects on atherogenesis, human apoA-I (AI) and human apoA-I and apoA-II (AI/AII) transgenic mice were produced in an atherosclerosis-susceptible strain. Following an atherogenic diet, despite similar total cholesterol and HDL cholesterol concentrations, the area of atherogenic lesions in the AI/AII mice was 15-fold greater than in the AI animals. These studies show that the protein composition of HDL significantly affects its role in atherogenesis and that AI-HDL is more antiatherogenic than AI/AII-HDL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413656     DOI: 10.1038/365762a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  52 in total

1.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

4.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

5.  The HDL proteome: a marker--and perhaps mediator--of coronary artery disease.

Authors:  Jay W Heinecke
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922

6.  Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism?

Authors:  Alan T Remaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

7.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.

Authors:  A Inazu; X C Jiang; T Haraki; K Yagi; N Kamon; J Koizumi; H Mabuchi; R Takeda; K Takata; Y Moriyama
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

9.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

10.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Authors:  L Berthou; N Duverger; F Emmanuel; S Langouët; J Auwerx; A Guillouzo; J C Fruchart; E Rubin; P Denèfle; B Staels; D Branellec
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.